India's $6 Trillion NCD Crisis: Healthcare Leaders Demand Preventive Focus in Union Budget 2026

Spread the Message

Read Time:4 Minute, 36 Second

As India gears up for the Union Budget 2026-27, healthcare industry leaders are sounding the alarm on non-communicable diseases (NCDs), projected to cause nearly 75% of the nation’s morbidity and mortality by 2030, with an staggering economic toll estimated at $6 trillion over the next decade.

This crisis, driven by cardiovascular diseases, diabetes, cancers, and chronic respiratory conditions, threatens India’s Viksit Bharat vision amid a population exceeding 1.4 billion.

The Mounting NCD Burden

NCDs already account for over 60% of deaths in India, rising from 37.9% in 1990 to 61.8% in 2016, with premature mortality between ages 30-70 affecting productive years. Recent surveys show hypertension prevalence at 35.5% (about 315 million adults) and diabetes impacting millions more, fueled by urbanization, poor diets, and sedentary lifestyles.

The economic impact is profound: older estimates peg losses at $4.58 trillion by 2030 from NCDs and mental health issues, with cardiovascular diseases alone costing $2.17 trillion in lost output and healthcare spending. Healthcare leaders now cite a $6 trillion figure over the coming decade, underscoring the urgency as NCDs strain families through high out-of-pocket expenses, often exceeding 60% of costs.

Voices from Healthcare Leaders

Dr. Azad Moopen, Founder and Chairman of Aster DM Healthcare, warns that intensifying pressures demand raising healthcare spending to 5% of GDP to fix infrastructure gaps and workforce shortages. He praises 2025’s GST 2.0 reforms exempting health insurance and cutting taxes on life-saving drugs but urges rationalized GST on diagnostics, incentives for tier-2/3 city investments, and focus on oncology, AI diagnostics, and geriatric care.

Ameera Shah, President of NATHEALTH and Executive Chairperson of Metropolis Healthcare, emphasizes shifting from episodic to preventive care, proposing an NCD resilience fund from health cess and CSR, plus ₹10,000 tax deductions for check-ups linked to Ayushman Bharat Health Account (ABHA). Dr. Rakesh Gupta, Chairman of Sarvodaya Hospital, calls for tax breaks on greenfield hospitals outside metros and duty waivers on imported devices to curb catastrophic expenditures.

MedTech voices like Himanshu Baid of Poly Medicure highlight inverted GST structures (5% on devices vs. 18% on inputs) and seek a ₹1,000-crore R&D fund, while Dev Tripathy of Philips pushes AI incentives for last-mile care.

Government Initiatives and Progress

India’s National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) targets screening 500 million people aged 30+ by 2025 for hypertension, diabetes, and common cancers via Ayushman Arogya Mandirs. The 75/25 initiative treated 42 million hypertensives and 25 million diabetics by 2025, nearing 90% targets, with digital tools and teleconsultations aiding follow-up.

A February 2025 intensified screening campaign aimed for 100% coverage of 30+ populations through door-to-door outreach by ASHA workers, real-time NP-NCD Portal tracking, and ensured supplies of BP monitors and glucometers. Ayushman Bharat Digital Mission integrates data for better management, though challenges persist in rural access and sustained treatment linkage.

Budget 2026: A Pivotal Opportunity

Leaders view Budget 2026 as a chance to treat healthcare as national infrastructure, with calls for higher public spending (last year exceeded ₹1 lakh crore across health sectors), primary care boosts, and digital interoperability. Expectations include PLI schemes for MedTech, NCD funds, duty rationalization on cancer equipment, and support for Heal in India to attract medical tourism.

Experts advocate capitated primary care payments, outcome-linked tertiary funding, and regulatory clarity for digital therapeutics to manage NCDs fiscally. This aligns with global WHO “best buys” like tobacco taxes and salt reduction, potentially cutting premature NCD deaths by 10-15%.

Public Health Implications

Preventive shifts could safeguard India’s demographic dividend, reducing disabilities, hospitalizations, and productivity losses while improving quality of life. For citizens, this means accessible screenings, affordable meds, and AI-driven early detection—practical steps like annual check-ups could avert complications.

Tier-2/3 expansions promise equitable care, curbing urban migration for treatment and easing metro overloads. Long-term, it positions India as a healthcare hub, blending Atmanirbhar manufacturing with exports.

Challenges and Balanced Perspectives

Despite progress, limitations loom: uneven screening coverage in rural areas, workforce shortages, and implementation gaps hinder NP-NCD goals. High out-of-pocket costs persist, with rural poor most vulnerable, and aging populations (65+ rising rapidly) will amplify demands.

Critics note public spending remains low (under 2% GDP), risking reliance on private sectors amid inverted duties stifling local MedTech. Conflicting priorities—like acute vs. preventive funding—require multi-sectoral action beyond budgets, including tobacco control and urban planning.

Skeptics question ROI without robust data governance under ABDM, urging evidence-based scaling.

Practical Advice for Readers

Health-conscious individuals can adopt low-cost preventives: balanced diets, 150 minutes weekly exercise, tobacco avoidance, and annual BP/glucose checks—especially post-30. Leverage ABHA-linked apps for tracking; families should prioritize screenings to cut familial burdens.

Consult GPs for personalized risks, as early intervention slashes costs—like managing prediabetes via lifestyle to avert full diabetes.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: